spacer
home > pmps > autumn 2018 > connecting medications
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Connecting Medications

Medication noncompliance is becoming an increasingly focussed concern in the healthcare sector for diverse reasons. Various studies targeting this issue in recent years have confirmed a particular picture: if the majority of research outcomes are correct and more than 50% of patients do not take their medications as prescribed, the economic and personal costs of inadequate patient adherence are enormous (1). In the US alone, the costs of medication noncompliance to the healthcare system are estimated to range between US $100 billion and US $290 billion annually (2). Furthermore, approximately 125,000 deaths and more than 10% of US hospitalisations per year are directly linked to nonadherence reasons (3). In addition to the adverse effects on public or private healthcare systems, medication noncompliance significantly impacts the profitability of pharmaceutical manufacturers.

Changing Traditional Business Models

Increasing cost pressures on healthcare systems and pharma companies from the market or policymakers, stringent regulatory requirements, and progressive digitalisation are massively changing traditional business models. From a blockbuster-driven past, a clear trend towards a pharma industry increasingly committed to producing value-added pharmaceuticals is now visibly emerging. Outcome-based drug pricing may help the pharma industry justify expensive therapies that often cost thousands of euros or dollars a month. On the other hand, healthcare systems are looking for ways to become more efficient by only paying the costs of medicines with proven positive effects. In this context, patient behaviour is of particular importance, as adherence to the prescribed medication decisively contributes to therapy, as well as, ultimately, economic success in clinical trials and commercial products.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Mathias Held is Business Development Manager for Patient Compliance Monitoring Solutions at Schreiner MediPharm, a business unit of Schreiner Group. He is in charge of developing new markets and business opportunities with a strong focus on smart packaging. Mathias has a degree in media technology from the Leipzig University of Applied Sciences, Germany.
spacer
Mathias Held
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Huge CPhI & P-MEC China a direct result of surging manufacturing

Shanghai, 22 July, 2019:CPhI and P-MEC China – organized by China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE), Informa Markets, and Shanghai Sinoexpo Informa Markets – saw record numbers of attendees as the pharma market in China continues to grow. The three-day Shanghai event featured 3,200+ exhibiting companies, spanning the entire pharma supply chain, and provides a strong indication of the market’s overall growth patterns and future development.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: 1st Quarter 2014

Synergy Research Group

In summary, Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement